Moscow, August 11 Russian President Vladimir Putin said on August 11 that the Russian Ministry of health has registered a new coronal vaccine developed in Russia for the first time. His daughter has been vaccinated and feels good, and hopes to start mass production in the near future. < / P > < p > according to the Russian President’s website on the 11th, Putin said during a video conference with a number of Russian government officials at the presidential residence in Moscow that day that the vaccine was developed by the “gamaliya” National Research Center for epidemiology and microbiology with adenovirus as the carrier, “the vaccine has passed the necessary tests, it can give full play to its function effectively and stably generate antibodies.”. < / P > < p > Putin said that one of his daughters participated in the vaccine trial and received two injections. “After the first injection, her temperature rose to 38 degrees Celsius, and the next day it dropped to more than 37 degrees Celsius. There was no other condition. After the second injection, the body temperature returned to normal and felt good after a slight rise, and the antibody level in the body was very high. Many of the subjects had normal body temperature after receiving the vaccine < p > < p > Ginzburg, director of the “gamaliya” center, said on the 7th that this vaccine belongs to the adenovirus vector vaccine, that is, the nucleic acid fragment encoding the spike protein of the new coronavirus is introduced into the adenovirus, and the adenovirus is used as the vector to induce the immune response of the human body to the spike protein of the new coronavirus. < / P > < p > according to Russian media reports, so far, 17 scientific research institutions in Russia are developing at least 26 new coronal vaccines, among which the “gamaliya” center has the fastest development progress. The phase 1 and phase 2 clinical trials of this vaccine in the “gamaliya” center ended on July 15 and August 3 respectively, meeting the safety and effectiveness standards of the Russian vaccine. According to the plan, the center will start a five month phase 3 clinical trial with about 2000 adults this month.